Dexcom, Inc.'s (NASDAQ:DXCM) fourth-quarter revenue rose 8% year-over-year to $1.114 billion, beating the analyst consensus ...

Dexcom designs and commercializes continuous glucose monitoring systems for diabetic patients. CGM systems serve as an ...

An innovative study, co-designed by Aboriginal Women, has led to remission of type 2 diabetes. The research described and ...

A new bill in Arkansas is the first on a state level to try and stem the “migration” of coverage for continuous glucose monitors to a pharmacy-only benefit.

Much progress has been made in diabetes technology over the past decade. Continuous glucose monitoring has achieved high accuracy and reliability, resulting ...

San Diego, California-based DexCom, Inc. (DXCM) is a medical device company that focuses on the design, development, and ...

Sales: The California-based device maker is pinning its hopes on Stelo, its recently launched device for adults aged 18 and ...

DexCom projects 2025 revenue of $4.6 billion, representing 14% growth. This forecast assumes strong demand for CGM systems, expanded reimbursement coverage, and a second-half launch of a 15-day G7 ...

Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of ...

Today, Benzinga's options scanner identified 8 options transactions for DexCom. This is an unusual occurrence. The sentiment ...

The quarter reflected steady revenue growth but underscored challenges in profit conversion, as seen in declining operating incomes. Despite these mixed results, DexCom's revenue trajectory indicates ...

Senseonics Holdings has filed for CE Mark registration for the Eversense 365 CGM system, paving the way for commercialization in European Union countries by Acensia Diabetes Care.